Lexaria Bioscience Corp. (LEXX) The Power of Science to Stop a Killer [Video Edition]

Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114 million adults in this country are at risk from damage caused by the long-term force of blood beating against artery walls, which often leads to disease and death. The good news is that hypertension is treatable and manageable through lifestyle changes and medications. Fact is, there are several approved blood pressure medications on the market, yet only about one in five people diagnosed with hypertension take medication. Why so few? Unfortunately, the side effects of these medications often outweigh the benefits. However, a new hypertension blockbuster may be imminent. A safer, better-tolerated drug candidate just marked a major milestone on the path to approval and commercialization. A global innovator in drug-delivery platforms, Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile) has been quietly progressing through clinical processes and amassing a growing body of evidence that strongly supports use of its patented DehydraTECH(TM) technology in hypertension therapeutics. The company’s valuation looks attractive with arguably significant upside as it looks to rub shoulders and gain attention from the likes of Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novartis AG (NYSE: NVS) — all aiming to capitalize on what may be the next blockbuster and defend hundreds of millions from a silent killer.